skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

In Honor of Psoriasis Awareness Month

Prevalent cases of psoriasis are anticipated to grow by 5.2% over the next decade in the US, Japan, and five major EU markets. To get a quick world view of the current psoriasis and psoriatic arthritis (PsA) landscape, download your COMPLIMENTARY infographic.

Get a clear perspective of the following:

  • Psoriasis severity prevalence proportions and total cases in 2016, by country (US, Germany, Italy, France, Spain, UK, Japan)
  • Psoriasis and PsA drugs in recently completed, ongoing, and planned registration studies (includes trials completed within the last two years)
  • Number of deals for psoriasis and psoriatic arthritis and average deal value
  • Partnered products
  • Psoriasis and PsA licensing deals by company types and role
  • The biosimilar landscape
  • Upcoming regulatory catalysts for biosimilars, including likelihood of approval (LOA) relative to average
  • Patients switched to etanercept biosimilar, by country